Arrowhead Pharmaceuticals (ARWR) PE Ratio: History & Chart

Arrowhead Pharmaceuticals, Inc.(ARWR)

Biotechnology · Pasadena, CA

$62.48+0.13 (+0.20%)

Delayed quote: Oct 6, 2026, 11:40 AM EDT

About Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States. The company's extensive therapeutic pipeline primarily leverages RNA interference (RNAi) technology. Among its advanced clinical programs are: ARO-AAT, a Phase II therapeutic targeting liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is undergoing both Phase 2b and Phase 3 clinical evaluations for hypertriglyceridemia; ARO-ANG3, currently in Phase 2b development to reduce the production of angiopoietin-like protein 3; and ARO-HIF2, a Phase 1b candidate designed to treat clear cell renal cell carcinoma. Arrowhead also has several compounds in earlier clinical development, including ARO-HSD in Phase 1/2a for other liver diseases, ARO-ENaC in Phase 1/2a, aimed at decreasing the epithelial sodium channel alpha subunit in lung airways, and ARO-C3, also in Phase 1/2a, for complement-mediated diseases. Further expanding its diverse portfolio, the company is actively developing ARO-Lung2 for chronic obstructive pulmonary disorder (COPD), ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-XDH for uncontrolled gout, and ARO-COV for COVID-19 and other pulmonary-borne pathogens. Beyond its core internal programs, Arrowhead is involved in the progression of JNJ-3989, a subcutaneously administered RNAi therapeutic for chronic hepatitis B virus infection; Olpasiran, intended to reduce apolipoprotein A production; and ARO-AMG1, which targets genetically validated cardiovascular pathways. Strategic collaborations are integral to Arrowhead's development efforts. The company holds a licensing and research agreement with Janssen Pharmaceuticals, Inc. for the co-development of ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3, all RNAi therapeutics focused on liver-expressed targets. Additionally, Arrowhead has a licensing and research partnership with Takeda Pharmaceuticals U.S.A., Inc. to develop an RNAi therapeutic candidate specifically for liver disease.

Pasadena, CA

711 employees

arrowheadpharma.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Christopher R. Anzalone

View full financials

NAME	MARKET CAP	PE RATIO	TTM	3Y	5Y
Arrowhead Pharmaceuticals, Inc. (ARWR)	$8.80B	N/A	41.90	41.90	41.90
Kymera Therapeutics, Inc. (KYMR)vs ›	$8.75B	N/A	N/A	N/A	N/A
Bruker Corporation (BRKRP)vs ›	$8.98B	N/A	552.62	552.62	552.62
Axsome Therapeutics, Inc. (AXSM)vs ›	$8.99B	N/A	N/A	N/A	N/A
Protagonist Therapeutics, Inc. (PTGX)vs ›	$9.00B	135.44	133.81	61.10	61.10
Oscar Health, Inc. (OSCR)vs ›	$8.44B	23.26	22.16	45.57	45.57
Bruker Corporation (BRKR)vs ›	$9.30B	N/A	54.08	39.03	41.91
Insulet Corp. (PODD)vs ›	$9.40B	25.38	58.80	65.23	3594.22
Caris Life Sciences, Inc. (CAI)vs ›	$8.00B	79.10	73.85	73.85	73.85
Praxis Precision Medicines, Inc. (PRAX)vs ›	$7.90B	N/A	N/A	N/A	N/A

NAME

MARKET CAP

PE RATIO

TTM

Arrowhead Pharmaceuticals, Inc. (ARWR)

$8.80B

N/A

41.90

Kymera Therapeutics, Inc. (KYMR)vs ›

$8.75B

N/A

Bruker Corporation (BRKRP)vs ›

$8.98B

N/A

552.62

Axsome Therapeutics, Inc. (AXSM)vs ›

$8.99B

N/A

Protagonist Therapeutics, Inc. (PTGX)vs ›

$9.00B

135.44

133.81

61.10

Oscar Health, Inc. (OSCR)vs ›

$8.44B

23.26

22.16

45.57

Bruker Corporation (BRKR)vs ›

$9.30B

N/A

54.08

39.03

41.91

Insulet Corp. (PODD)vs ›

$9.40B

25.38

58.80

65.23

3594.22

Caris Life Sciences, Inc. (CAI)vs ›

$8.00B

79.10

73.85

Praxis Precision Medicines, Inc. (PRAX)vs ›

$7.90B

N/A

PE Ratio Formula & Definition

PE Ratio = Share Price / Diluted EPS (TTM)

The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.

PE Ratio FAQ

What is the P/E ratio for Arrowhead Pharmaceuticals, Inc. (ARWR)?

The P/E ratio for ARWR stock is N/A.

What is the TTM average P/E ratio for Arrowhead Pharmaceuticals, Inc. (ARWR)?

The TTM average P/E ratio for ARWR stock is 41.90.

What is the 3Y average P/E ratio for Arrowhead Pharmaceuticals, Inc. (ARWR)?

The 3Y average P/E ratio for ARWR stock is 41.90.

What is the 5Y average P/E ratio for Arrowhead Pharmaceuticals, Inc. (ARWR)?

The 5Y average P/E ratio for ARWR stock is 41.90.

DATE	PE RATIO
2026-05-07	50.62
2026-05-06	51.39
2026-05-05	48.66
2026-05-04	49.60
2026-05-01	48.58
2026-04-30	47.71
2026-04-29	45.80
2026-04-28	45.54
2026-04-27	47.79
2026-04-24	47.99
2026-04-23	48.31
2026-04-22	48.00
2026-04-21	46.14
2026-04-20	44.97
2026-04-17	45.14
2026-04-16	44.14
2026-04-15	46.07
2026-04-14	43.31
2026-04-13	41.42
2026-04-10	42.30
2026-04-09	43.01
2026-04-08	41.79
2026-04-07	39.73
2026-04-06	39.69
2026-04-02	39.63
2026-04-01	40.86
2026-03-31	40.71
2026-03-30	37.44
2026-03-27	37.52
2026-03-26	39.46
2026-03-25	39.46
2026-03-24	36.54
2026-03-23	36.80
2026-03-20	36.58
2026-03-19	36.99
2026-03-18	36.82
2026-03-17	37.38
2026-03-16	37.25
2026-03-13	35.75
2026-03-12	35.72
2026-03-11	37.73
2026-03-10	38.44
2026-03-09	39.40
2026-03-06	38.84
2026-03-05	41.30
2026-03-04	42.27
2026-03-03	41.62
2026-03-02	41.77
2026-02-27	41.08
2026-02-26	41.16
2026-02-25	40.01
2026-02-24	41.34
2026-02-23	41.00
2026-02-20	41.29
2026-02-19	41.47
2026-02-18	41.81
2026-02-17	41.36
2026-02-13	41.44
2026-02-12	40.51
2026-02-11	39.97
2026-02-10	40.86
2026-02-09	40.68
2026-02-06	41.90
2020-08-05	424.98
2020-08-04	430.44
2020-08-03	432.98
2020-07-31	420.20
2020-07-30	443.41
2020-07-29	432.20
2020-07-28	444.00
2020-07-27	471.61
2020-07-24	450.83
2020-07-23	455.22
2020-07-22	474.15
2020-07-21	475.61
2020-07-20	500.20
2020-07-17	478.24
2020-07-16	478.24
2020-07-15	470.05
2020-07-14	461.85
2020-07-13	450.05
2020-07-10	434.24
2020-07-09	440.49
2020-07-08	441.46
2020-07-07	431.61
2020-07-06	426.54
2020-07-02	431.22
2020-07-01	430.83
2020-06-30	421.37
2020-06-29	415.61
2020-06-26	422.15
2020-06-25	412.00
2020-06-24	387.90
2020-06-23	407.41
2020-06-22	388.59
2020-06-19	358.34
2020-06-18	358.24
2020-06-17	346.44
2020-06-16	348.78
2020-06-15	324.10
2020-06-12	319.32
2020-06-11	308.10
2020-06-10	341.56
2020-06-09	342.83
2020-06-08	348.68
2020-06-05	332.39
2020-06-04	316.59
2020-06-03	312.29
2020-06-02	319.71
2020-06-01	324.98
2020-05-29	314.54
2020-05-28	322.83
2020-05-27	328.49
2020-05-26	328.88
2020-05-22	348.20
2020-05-21	349.66
2020-05-20	357.37
2020-05-19	356.00
2020-05-18	373.07
2020-05-15	349.76
2020-05-14	347.32
2020-05-13	333.22
2020-05-12	350.63
2020-05-11	354.15
2020-05-08	333.07
2020-05-07	64.76
2020-05-06	63.10
2020-05-05	65.25
2020-05-04	62.97
2020-05-01	60.02
2020-04-30	63.47
2020-04-29	67.34
2020-04-28	68.68
2020-04-27	72.76
2020-04-24	71.69
2020-04-23	70.88
2020-04-22	68.09
2020-04-21	67.50
2020-04-20	71.69
2020-04-17	67.37
2020-04-16	64.20
2020-04-15	65.12
2020-04-14	67.78
2020-04-13	64.24
2020-04-09	62.43
2020-04-08	58.08
2020-04-07	54.18
2020-04-06	53.35
2020-04-03	48.15
2020-04-02	49.60
2020-04-01	48.88
2020-03-31	53.03
2020-03-30	53.40
2020-03-27	51.83
2020-03-26	56.39
2020-03-25	53.86
2020-03-24	52.77
2020-03-23	47.15
2020-03-20	51.23
2020-03-19	47.93
2020-03-18	37.90
2020-03-17	40.50
2020-03-16	40.11
2020-03-13	48.52
2020-03-12	46.10
2020-03-11	52.65
2020-03-10	55.10
2020-03-09	55.30
2020-03-06	61.57
2020-03-05	65.60
2020-03-04	68.07
2020-03-03	64.79
2020-03-02	65.44
2020-02-28	65.18
2020-02-27	66.36
2020-02-26	66.47
2020-02-25	62.89
2020-02-24	67.08
2020-02-21	70.95
2020-02-20	73.25
2020-02-19	73.60
2020-02-18	74.75
2020-02-14	76.07
2020-02-13	75.67
2020-02-12	78.18
2020-02-11	76.65
2020-02-10	78.99
2020-02-07	74.53
2020-02-06	75.76
2020-02-05	62.46
2020-02-04	62.71
2020-02-03	61.80
2020-01-31	59.87
2020-01-30	59.31
2020-01-29	62.91
2020-01-28	64.86
2020-01-27	62.87
2020-01-24	63.73
2020-01-23	66.01
2020-01-22	67.97
2020-01-21	67.99
2020-01-17	80.60
2020-01-16	81.59
2020-01-15	81.33
2020-01-14	82.14
2020-01-13	80.94
2020-01-10	82.87
2020-01-09	84.20
2020-01-08	85.43
2020-01-07	85.11
2020-01-06	84.91
2020-01-03	87.94
2020-01-02	90.17
2019-12-31	90.61
2019-12-30	91.71
2019-12-27	92.76
2019-12-26	95.70
2019-12-24	92.23
2019-12-23	91.09
2019-12-20	90.70
2019-12-19	96.69
2019-12-18	95.01
2019-12-17	94.07
2019-12-16	93.40
2019-12-13	94.94
2019-12-12	96.17
2019-12-11	97.46
2019-12-10	101.23
2019-12-09	96.81
2019-12-06	96.10
2019-12-05	93.61
2019-12-04	94.94
2019-12-03	98.09
2019-12-02	90.47
2019-11-29	104.30
2019-11-27	98.60
2019-11-26	96.71
2019-11-25	121.26
2019-11-22	104.68
2019-11-21	104.38
2019-11-20	102.87
2019-11-19	107.45
2019-11-18	102.49
2019-11-15	100.94
2019-11-14	103.19
2019-11-13	103.21
2019-11-12	96.33
2019-11-11	91.36
2019-11-08	89.57
2019-11-07	84.26
2019-11-06	83.45
2019-11-05	84.53
2019-11-04	83.96
2019-11-01	88.26
2019-10-31	85.21
2019-10-30	85.17
2019-10-29	84.89
2019-10-28	83.53
2019-10-25	82.02
2019-10-24	78.45

DATE

PE RATIO

2026-05-07

50.62

2026-05-06

51.39

2026-05-05

48.66

2026-05-04

49.60

2026-05-01

48.58

2026-04-30

47.71

2026-04-29

45.80

2026-04-28

45.54

2026-04-27

47.79

2026-04-24

47.99

2026-04-23

48.31

2026-04-22

48.00

2026-04-21

46.14

2026-04-20

44.97

2026-04-17

45.14

2026-04-16

44.14

2026-04-15

46.07

2026-04-14

43.31

2026-04-13

41.42

2026-04-10

42.30

2026-04-09

43.01

2026-04-08

41.79

2026-04-07

39.73

2026-04-06

39.69

2026-04-02

39.63

2026-04-01

40.86

2026-03-31

40.71

2026-03-30

37.44

2026-03-27

37.52

2026-03-26

39.46

2026-03-25

39.46

2026-03-24

36.54

2026-03-23

36.80

2026-03-20

36.58

2026-03-19

36.99

2026-03-18

36.82

2026-03-17

37.38

2026-03-16

37.25

2026-03-13

35.75

2026-03-12

35.72

2026-03-11

37.73

2026-03-10

38.44

2026-03-09

39.40

2026-03-06

38.84

2026-03-05

41.30

2026-03-04

42.27

2026-03-03

41.62

2026-03-02

41.77

2026-02-27

41.08

2026-02-26

41.16

2026-02-25

40.01

2026-02-24

41.34

2026-02-23

41.00

2026-02-20

41.29

2026-02-19

41.47

2026-02-18

41.81

2026-02-17

41.36

2026-02-13

41.44

2026-02-12

40.51

2026-02-11

39.97

2026-02-10

40.86

2026-02-09

40.68

2026-02-06

41.90

2020-08-05

424.98

2020-08-04

430.44

2020-08-03

432.98

2020-07-31

420.20

2020-07-30

443.41

2020-07-29

432.20

2020-07-28

444.00

2020-07-27

471.61

2020-07-24

450.83

2020-07-23

455.22

2020-07-22

474.15

2020-07-21

475.61

2020-07-20

500.20

2020-07-17

478.24

2020-07-16

478.24

2020-07-15

470.05

2020-07-14

461.85

2020-07-13

450.05

2020-07-10

434.24

2020-07-09

440.49

2020-07-08

441.46

2020-07-07

431.61

2020-07-06

426.54

2020-07-02

431.22

2020-07-01

430.83

2020-06-30

421.37

2020-06-29

415.61

2020-06-26

422.15

2020-06-25

412.00

2020-06-24

387.90

2020-06-23

407.41

2020-06-22

388.59

2020-06-19

358.34

2020-06-18

358.24

2020-06-17

346.44

2020-06-16

348.78

2020-06-15

324.10

2020-06-12

319.32

2020-06-11

308.10

2020-06-10

341.56

2020-06-09

342.83

2020-06-08

348.68

2020-06-05

332.39

2020-06-04

316.59

2020-06-03

312.29

2020-06-02

319.71

2020-06-01

324.98

2020-05-29

314.54

2020-05-28

322.83

2020-05-27

328.49

2020-05-26

328.88

2020-05-22

348.20

2020-05-21

349.66

2020-05-20

357.37

2020-05-19

356.00

2020-05-18

373.07

2020-05-15

349.76

2020-05-14

347.32

2020-05-13

333.22

2020-05-12

350.63

2020-05-11

354.15

2020-05-08

333.07

2020-05-07

64.76

2020-05-06

63.10

2020-05-05

65.25

2020-05-04

62.97

2020-05-01

60.02

2020-04-30

63.47

2020-04-29

67.34

2020-04-28

68.68

2020-04-27

72.76

2020-04-24

71.69

2020-04-23

70.88

2020-04-22

68.09

2020-04-21

67.50

2020-04-20

71.69

2020-04-17

67.37

2020-04-16

64.20

2020-04-15

65.12

2020-04-14

67.78

2020-04-13

64.24

2020-04-09

62.43

2020-04-08

58.08

2020-04-07

54.18

2020-04-06

53.35

2020-04-03

48.15

2020-04-02

49.60

2020-04-01

48.88

2020-03-31

53.03

2020-03-30

53.40

2020-03-27

51.83

2020-03-26

56.39

2020-03-25

53.86

2020-03-24

52.77

2020-03-23

47.15

2020-03-20

51.23

2020-03-19

47.93

2020-03-18

37.90

2020-03-17

40.50

2020-03-16

40.11

2020-03-13

48.52

2020-03-12

46.10

2020-03-11

52.65

2020-03-10

55.10

2020-03-09

55.30

2020-03-06

61.57

2020-03-05

65.60

2020-03-04

68.07

2020-03-03

64.79

2020-03-02

65.44

2020-02-28

65.18

2020-02-27

66.36

2020-02-26

66.47

2020-02-25

62.89

2020-02-24

67.08

2020-02-21

70.95

2020-02-20

73.25

2020-02-19

73.60

2020-02-18

74.75

2020-02-14

76.07

2020-02-13

75.67

2020-02-12

78.18

2020-02-11

76.65

2020-02-10

78.99

2020-02-07

74.53

2020-02-06

75.76

2020-02-05

62.46

2020-02-04

62.71

2020-02-03

61.80

2020-01-31

59.87

2020-01-30

59.31

2020-01-29

62.91

2020-01-28

64.86

2020-01-27

62.87

2020-01-24

63.73

2020-01-23

66.01

2020-01-22

67.97

2020-01-21

67.99

2020-01-17

80.60

2020-01-16

81.59

2020-01-15

81.33

2020-01-14

82.14

2020-01-13

80.94

2020-01-10

82.87

2020-01-09

84.20

2020-01-08

85.43

2020-01-07

85.11

2020-01-06

84.91

2020-01-03

87.94

2020-01-02

90.17

2019-12-31

90.61

2019-12-30

91.71

2019-12-27

92.76

2019-12-26

95.70

2019-12-24

92.23

2019-12-23

91.09

2019-12-20

90.70

2019-12-19

96.69

2019-12-18

95.01

2019-12-17

94.07

2019-12-16

93.40

2019-12-13

94.94

2019-12-12

96.17

2019-12-11

97.46

2019-12-10

101.23

2019-12-09

96.81

2019-12-06

96.10

2019-12-05

93.61

2019-12-04

94.94

2019-12-03

98.09

2019-12-02

90.47

2019-11-29

104.30

2019-11-27

98.60

2019-11-26

96.71

2019-11-25

121.26

2019-11-22

104.68

2019-11-21

104.38

2019-11-20

102.87

2019-11-19

107.45

2019-11-18

102.49

2019-11-15

100.94

2019-11-14

103.19

2019-11-13

103.21

2019-11-12

96.33

2019-11-11

91.36

2019-11-08

89.57

2019-11-07

84.26

2019-11-06

83.45

2019-11-05

84.53

2019-11-04

83.96

2019-11-01

88.26

2019-10-31

85.21

2019-10-30

85.17

2019-10-29

84.89

2019-10-28

83.53

2019-10-25

82.02

2019-10-24

78.45

PE Ratio: N/A

ARWR PE Ratio Chart

ARWR Average PE Ratio Chart

ARWR PE Ratio Metrics

ARWR Competitors' PE Ratio

P/E Comparison

Forward P/E Calculation

PE Ratio Formula & Definition

PE Ratio FAQ

ARWR PE Ratio History

Related Metrics